MENS Stock Forecast: Jyong Biotech Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.45
−17.14% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$110.2M
Ticker Nerd rank
4/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−17.6%
1M
−22.0%
YTD
−63.3%
1Y
−95.6%
From 52W high
−95.9%
From 52W low
0.0%
$1
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Jyong Biotech Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
4/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
31
Issuance
27
Revisions
20
Volatility
15
Quality
13
Growth
10
Momentum
8
Accruals
5

Value (31): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (5): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MENS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MENS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Jan 26Apr 26Jul 26Oct 26MENS

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MENS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MENS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Jyong Biotech Ltd. returned −95.6% against +6.9% for the S&P 500, dividends included.

MENS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26MENSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MENS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−12.0%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jyong Biotech Ltd. has a market value of $110.2M and an enterprise value of $147.3M.

  • Shares outstanding: 74.2M.

  • Jyong Biotech Ltd. employs 27 people.

market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MENS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MENSJyong Biotech Ltd.$110.2M4
FATEFate Therapeutics, Inc.$106.8M85
CDXSCodexis, Inc.$108.6M41
OKUROnKure Therapeutics, Inc.$109.0M53
SPRBSpruce Biosciences, Inc.$109.2M14
ARMPArmata Pharmaceuticals, Inc.$111.0M86
IMUXImmunic, Inc.$111.0M21

Take a look at MENS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Jyong Biotech Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MENS

How does Ticker Nerd's model rank MENS?

As at 21 Nov 2026, Jyong Biotech Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (31 of 100).

What is the MENS stock forecast for 2030?

No analyst covering Jyong Biotech Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MENS are extrapolating price history, which says nothing about the business.

How has MENS stock performed over the past year?

Jyong Biotech Ltd. returned -95.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jyong Biotech Ltd. do?

Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases. Its current product pipeline includes candidate therapies for benign prostatic hyperplasia and lower urinary tract symptoms, prostate cancer, and interstitial cystitis or bladder pain syndrome.

Company

About Jyong Biotech Ltd.

Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases. Its current product pipeline includes candidate therapies for benign prostatic hyperplasia and lower urinary tract symptoms, prostate cancer, and interstitial cystitis or bladder pain syndrome. The company concentrates on botanical drug development, combining research and commercialization efforts around differentiated therapeutics designed for unmet medical needs. Jyong Biotech Ltd. operates with an initial commercial focus on the United States, the European Union, and Asia, including Taiwan and mainland China. As a specialized biopharmaceutical firm, it plays a role in advancing novel natural-origin treatments within the broader pharmaceuticals and biotechnology market.

CEO Ms. Fu-Feng Kuo · 27 employees · Taiwan · https://jyongbio.com